WAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC

Clinical trial NCT07330050 · RECRUITING

Trial details

NCT number: NCT07330050
Sponsor: Tianjin Medical University Cancer Institute and Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

NSCLC (Non-small Cell Lung Cancer)

Start date: 2025-12-01
Primary completion: 2026-12-31
Enrollment: 31

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.